38 / 40
RESEARCH ARTICLE
SA JOURNAL OF DIABETES & VASCULAR DISEASE
80
VOLUME 16 NUMBER 2 • NOVEMBER 2019
References
1. Farhan S, Höchtl T, Kautzky-Willer A, Wojta J, Huber K. Antithrombotic therapy
in patients with coronary artery disease and with type 2 diabetes mellitus.
Wien
Med Chenschr
2010;
160
: 30–38.
2. Ergelen M, Uyarel H, Cicek G, Isik T, Osmonov D, Gunaydin ZY,
et al
. Which is
worst in patients undergoing primary angioplasty for acute myocardial infarction?
Hyperglycaemia? Diabetes mellitus? Or both?
Acta Cardiol
2010;
65
: 415–423.
3. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B,
et al
. 2011
ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of
the American College of Cardiology Foundation/ American Heart Association task
force on practice guidelines and the society for cardiovascular angiography and
interventions.
Circulation
2011;
124
(23): 574–651.
4. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A,
et al
.
Link between the angiographic sub study and mortality outcomes in a large
randomized trial of myocardial reperfusion. Importance of early and complete
infarct artery reperfusion. GUSTO-I investigators.
Circulation
1995;
91
: 1923–
1928.
5. Brener SJ, Mehran R, Dressler O, Cristea E, Stone GW. Diabetes mellitus,
myocardial reperfusion, and outcome in patients with acute ST-elevation
myocardial infarction treated with primary angioplasty (from HORIZONS AMI).
Am J Cardiol
2012;
109
: 1111–1116.
6. Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M,
et al
. Glycoprotein
IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis
and improve coronary flow in diabetics: the ‘OPTIMIZE-IT’ pilot randomized study.
J Cardiovasc Med
(Hagerstown) 2009;
10
: 245–251.
7. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J,
et al
. Effect of intracoronary
tirofiban in patients undergoing percutaneous coronary intervention for acute
coronary syndrome.
Circ J
2008;
72
: 1605–1609.
8. Kirma C, Erkol A, Pala S, Oduncu V, Du¨ndar C, Izgi A,
et al
. Intracoronary bolus-
only compared with intravenous bolus plus infusion of tirofiban application in
patients with ST-elevation myocardial infarction undergoing primary percutaneous
coronary intervention.
Catheter Cardiovasc Interv
2011;
79
: 59–67.
9. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA,
et
al
. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial
infarction: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines.
Circulation
2013;
127
: 362–425.
10. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR
Jr,
et al
. 2014 AHA/ACC guideline for the management of patients with non-
ST-elevation acute coronary syndromes: a report of the American College
of Cardiology/American Heart Association task force on practice guidelines.
Circulation
2014;
130
: 344–426.
11. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F,
et al
.
2015 ESC guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation: task force for
the management of acute coronary syndromes in patients presenting without
persistent ST-segment elevation of the European Society of Cardiology (ESC).
Eur
Heart J
2016;
37
: 267–315.
12. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA,
et
al
. ESC guidelines for the management of acute myocardial infarction in patients
presenting with ST-segment elevation.
Eur Heart J
2012;
33
: 2569–619.
13. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, the writing
group on behalf of the joint ESC/ACCF/AHA/WHF task force for the universal
definition of myocardial infarction: Third universal definition of myocardial
infarction.
Eur Heart J
2012;
33
: 2551–2556.
14. TIMI study group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I
findings.
N Engl J Med
1985;
312
(14): 932–936.
15. Van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F.
Angiographic assessment of myocardial reperfusion in patients treated with
primary angioplasty for acute myocardial infarction: myocardial blush grade.
Zwolle myocardial infarction study group. Circulation 1998; 97: 2302–2306.
16. Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU,
et al
. Single high-
dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary
angioplasty.
Heart Vessels
2006;
21
: 102–107.
17. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A,
et al
.. 2014
ACC/AHA key data elements and definitions for cardiovascular endpoint
events in clinical trials: A report of the American College of Cardiology/
American Heart Association task force on clinical data standards (writing
committee to develop cardiovascular endpoints data standards).
Circulation
2015;
132
(4): 302–361.
18. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J,
et al
.
Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: A comparison between
intravenous tissue plasminogen activator and intravenous streptokinase. Clinical
findings through hospital discharge.
Circulation
1987;
76
: 142–154.
19. Zalewski J, Nycz K, Przewlocki T,
et al
. Evolution of myocardial perfusion
during primary angioplasty in spontaneously reperfused infarct-related artery:
impact on long-term clinical outcomes and left ventricular function recovery.
Int J Cardiol
2011;
147
: 25–31.
20. Ding S, Pu J, Qiao ZQ,
et al
. TIMI myocardial perfusion frame count: a new
method to assess myocardial perfusion and its predictive value for short-term
prognosis.
Catheter Cardiovasc Interv
2010;
75
: 722–732.
21. Mokadam NA, Melford RE Jr, Maynard C,
et al
. Prevalence and procedural
outcomes of percutaneous coronary intervention and coronary artery bypass
grafting in patients with diabetes and multivessel coronary artery disease.
J Card
Surg
2011;
26
: 1–8.
22. Timmer JR, Ten Berg J, Heestermans AA,
et al
. Pre-hospital administration of
tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing
primary angioplasty: a subanalysis of the on-time 2 trial.
EuroIntervention
2010;
6
: 336–342.
23. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects
of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion.
A quantitative myocardial contrast echocardiography study.
J Am Coll Cardiol
2004;
43
: 276–283.
24. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ,
et
al
. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation
myocardial infarction: a meta-analysis of randomized trials.
J Am Med Assoc
2005;
293
: 1759–1765.
25. Topol EJ, Moliterno DJ, Hermann HC,
et al
. Comparison of two platelet
glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of
ischemic events with percutaneous coronary revascularization.
N Engl J Med
2001;
344
: 1888–1894.
26. Sharma S, Makkar R, Lardizabal J. Intracoronary administration of abciximab
during percutaneous coronary interventions: should this be the routine and
preferred approach?
J Cardiovasc Pharmacol Ther
2006;
11
: 136–141.
27. Hu S, Wang H, Zhu J, Li M, Li H, Gao D, Zhang H. Effect of intracoronary
administration of tirofiban through aspiration catheter on patients over 60
years with ST-segment elevation myocardial infarction undergoing percutaneous
coronary intervention.
Medicine
(Baltimore) 2018;
97
(21): e10850.
28. Wilmer CI. Intracoronary high-dose bolus tirofiban administration during complex
coronary interventions: A United States-based case series.
Cardiovasc Revasc Med
2018;
19
(1 Pt B): 112–116.
29. Zalewski J, Nycz K, Przewlocki T,
et al
. Evolution of myocardial perfusion during
primary angioplasty in spontaneously reperfused infarct-related artery: impact on
long-term clinical outcomes and left ventricular function recovery.
Int J Cardiol
2011;
147
: 25–31.
30. Huang SS, Leu HB, Lu TM,
et al
. The impacts of in-hospital invasive strategy
on long-term outcome in elderly patients with non-ST-elevation myocardial
infarction.
Acta Cardiol Sin
2013;
29
: 115–123.
31. PROVE IT–TIMI 22 investigators. C-reactive protein levels and outcomes after
statin therapy.
N Engl J Med
2005;
352
: 20–28.
32. Ridker PM, Hennekens CH, Buring JE,
et al
. C-reactive protein and other markers
of inflammation in the prediction of cardiovascular disease in women.
N Engl J
Med
2000;
342
: 836–843.
33. Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB,
et al
. The
relative effects of abciximab and tirofiban on platelet inhibition and C-reactive
protein during coronary intervention.
J Invasive Cardiol
2010;
22
(1): 2–6.
34. Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban on C-reactive
protein in non-ST-elevation myocardial infarction.
Am Heart J
2004;
147
(1): e1.